Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

Phase 2 Completed 10 enrolled Medical University of South Carolina Merck Sharp & Dohme LLC · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

OBJECTIVES: I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral density of the hip and spine in children with high-turnover idiopathic juvenile osteoporosis.

Timeline

Start: 2000-09
Primary completion: 2003-10
Completion: 2008-11

Publications

Results Key LL Jr, Ries W, Madyastha P, Reed F. Juvenile osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May;16 Suppl 3:683-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alendronic Acid	Small molecule	35 mg	Oral
Subject	Alendronic Acid	Small molecule	70 mg	Oral

Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis

Summary

Timeline

Publications

Drugs

Indications